Sec Form 4 Filing - Kummeth Charles R. @ BIO-TECHNE Corp - 2019-07-08

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Kummeth Charles R. 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) 614 MCKINLEY PL NE 3. Date of Earliest Transaction (MM/DD/YY) 07/08/2019 (Street) MINNEAPOLIS, MN55413 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/08/2019 M 17,994 A $ 67.46 110,170 ( 1 ) D Common Stock 07/08/2019 S( 2 ) 17,994 D $ 212.7478 ( 3 ) 92,176 ( 1 ) D Common Stock 07/09/2019 M 15,037 A $ 67.46 107,213 ( 1 ) D Common Stock 07/09/2019 S( 2 ) 15,037 D $ 212.432 ( 4 ) 92,176 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (Right to buy) $ 67.46 07/08/2019 M 17,994 ( 5 ) 04/01/2020 Common Stock 17,994 $ 0 32,006 D Stock Options (Right to buy) $ 67.46 07/09/2019 M 15,037 ( 5 ) 04/01/2020 Common Stock 15,037 $ 0 16,969 D Restricted Stock Units ( 6 ) ( 7 ) ( 7 ) Common Stock 24,979 24,979 D Restricted Stock Units ( 6 ) ( 8 ) ( 8 ) Common Stock 21,291 21,291 D Restricted Stock Units ( 6 ) ( 9 ) ( 9 ) Common Stock 16,918 16,918 D Stock Option (Right to Buy) $ 108.49 ( 10 ) 08/07/2022 Common Stock 79,517 79,517 D Stock Option (Right to Buy) $ 106.59 ( 11 ) 08/18/2023 Common Stock 102,779 102,779 D Stock Option (Right to Buy) $ 106.59 ( 7 ) 08/18/2023 Common Stock 154,169 154,169 D Stock Option (Right to Buy) $ 86.25 ( 5 ) 04/01/2021 Common Stock 46,316 46,316 D Stock Option (Right to Buy) $ 67.46 ( 5 ) 04/01/2020 Common Stock 65,000 65,000 D Stock Options (Right to buy) $ 177.32 ( 12 ) 08/08/2025 Common Stock 60,222 60,222 D Stock Options (Right to buy) $ 177.32 ( 9 ) 08/08/2025 Common Stock 90,334 90,334 D Stock Options (Right to buy) $ 125.05 ( 8 ) 08/09/2024 Common Stock 117,342 117,342 D Stock Options (Right to buy) $ 125.05 ( 13 ) 08/09/2024 Common Stock 78,228 78,228 D Stock Options (Right to buy) $ 94.35 ( 5 ) 08/12/2021 Common Stock 66,849 66,849 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Kummeth Charles R. 614 MCKINLEY PL NE MINNEAPOLIS, MN55413 X Chief Executive Officer Signatures /s/ Brenda S. Furlow, attorney in fact for Charles R. Kummeth pursuant to Power of Attorney previously filed 07/10/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. ( 2 )The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. ( 3 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.00 to $214.125, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. ( 4 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.00 to $213.58, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. ( 5 )Fully exercisable ( 6 )Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. ( 7 )Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 8 )Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 9 )Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 10 )Vests 19,879 shares on each of 8/7/16, 8/7/17 and 8/7/18 and 19,880 shares on 8/7/19. ( 11 )Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20. ( 12 )Vests 15,056 shares each on 8/8/2019, 8/8/202 and 15,055 shares each on 8/8/2021, 8/8/2022 ( 13 )Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.